{
  "ticker": "LLY",
  "target_date": "2025-02-05",
  "actual_date": "2025-02-05",
  "collected_at": "2025-12-08T11:21:59.780885",
  "price": {
    "open": 828.97,
    "high": 840.63,
    "low": 824.91,
    "close": 835.9448852539062,
    "volume": 4578900,
    "change_1d_pct": 1.95,
    "change_7d_pct": 4.21,
    "change_30d_pct": 11.17
  },
  "technicals": {
    "rsi_14": 74.73,
    "sma_20": 779.76,
    "sma_50": 780.0,
    "macd": 12.778,
    "macd_signal": 5.306,
    "macd_histogram": 7.473,
    "bb_upper": 844.19,
    "bb_lower": 715.32,
    "price_vs_sma20_pct": 7.21,
    "price_vs_sma50_pct": 7.17,
    "volume_ratio": 1.13
  },
  "fundamentals": {
    "market_cap": 890934591488,
    "pe_ratio": 48.69378,
    "forward_pe": 43.858784,
    "price_to_book": 37.41868,
    "price_to_sales": 14.993901,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.63,
    "pct_from_52w_low": 59.33
  },
  "macro": {
    "spy": {
      "price": 598.97,
      "change_1d_pct": 0.41,
      "change_7d_pct": -0.05
    },
    "vix": {
      "level": 15.77,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.42
    },
    "dollar_index": {
      "level": 107.58
    },
    "gold": {
      "price": 2871.6
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Fidelity Contrafund Q4 2024 Review",
      "source": "SeekingAlpha",
      "datetime": 1738794900,
      "summary": "For Q4 2024, the Fidelity Contrafund's Retail Class shares gained 3.56%, topping the 2.41% advance of the S&P 500\u00c2\u00ae index. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=3a0a5a73483fa9fd7e332d0b4cf17231696a722fb5cfb954e54a0be6eb6011ff"
    },
    {
      "headline": "Novo Nordisk: Among The Best Opportunities Of The Moment (Rating Upgrade)",
      "source": "SeekingAlpha",
      "datetime": 1738755928,
      "summary": "Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=c964cf4a3b1ab972ec47e0826d1246cae4dd1a3013683d744db7f02d83da5dfd"
    },
    {
      "headline": "Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA",
      "source": "MarketWatch",
      "datetime": 1738754040,
      "summary": "Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA",
      "url": "https://finnhub.io/api/news?id=2fa33e571cd7d8d171ed1b76da7625eeca848b707eeb38aae975165b4458e3d8"
    },
    {
      "headline": "Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today",
      "source": "SeekingAlpha",
      "datetime": 1738750393,
      "summary": "Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO stock from hold to buy.",
      "url": "https://finnhub.io/api/news?id=8f01c95d1cca4944d0b96bac91965e0bcb3286752ac3796055c8f8c08ee49963"
    },
    {
      "headline": "Fidelity Blue Chip Growth Fund Q4 2024 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1738746600,
      "summary": "For Q4 2024, the Fidelity Blue Chip Growth Fund's Retail Class shares gained 9.12%, handily outpacing the benchmark. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=3fe7acc1f518c5b79647875f00651e8380ca832b0db7920c13dff2215f8c56ae"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-02-04",
      "description": "xslF345X05/wk-form4_1738704486.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000034/xslF345X05/wk-form4_1738704486.xml"
    },
    {
      "form": "4",
      "date": "2025-02-04",
      "description": "xslF345X05/wk-form4_1738704436.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000032/xslF345X05/wk-form4_1738704436.xml"
    },
    {
      "form": "4",
      "date": "2025-02-04",
      "description": "xslF345X05/wk-form4_1738704376.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000030/xslF345X05/wk-form4_1738704376.xml"
    },
    {
      "form": "4",
      "date": "2025-02-04",
      "description": "xslF345X05/wk-form4_1738704326.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000028/xslF345X05/wk-form4_1738704326.xml"
    },
    {
      "form": "4",
      "date": "2025-02-04",
      "description": "xslF345X05/wk-form4_1738704275.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000026/xslF345X05/wk-form4_1738704275.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}